Production (Stage)
Protara Therapeutics, Inc.
TARA
$3.34
$0.2156.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.28% | 3.28% | -4.95% | -12.65% | -10.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.18% | 29.63% | 15.23% | -12.18% | 21.77% |
| Operating Income | -19.18% | -29.63% | -15.23% | 12.18% | -21.77% |
| Income Before Tax | -7.38% | -24.93% | -13.78% | 15.77% | -22.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.38% | -24.93% | -13.78% | 15.77% | -22.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.38% | -24.93% | -13.78% | 15.77% | -22.66% |
| EBIT | -19.18% | -29.63% | -15.23% | 12.18% | -21.77% |
| EBITDA | -19.32% | -30.14% | -15.30% | 12.30% | -21.89% |
| EPS Basic | 69.87% | 46.28% | 42.18% | 55.15% | -21.41% |
| Normalized Basic EPS | 69.88% | 46.29% | 42.18% | 55.14% | -21.42% |
| EPS Diluted | 69.87% | 46.28% | 42.18% | 55.15% | -21.41% |
| Normalized Diluted EPS | 69.88% | 46.29% | 42.18% | 55.14% | -21.42% |
| Average Basic Shares Outstanding | 256.43% | 132.58% | 96.77% | 87.77% | 1.04% |
| Average Diluted Shares Outstanding | 256.43% | 132.58% | 96.77% | 87.77% | 1.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |